Image goes here

Covid-19 Advice from Funders

Please check this page regularly for the latest advice from our Funders


Funders are very aware that these are challenging times for grant-holders and are doing their best to be flexible and provide advice and guidance. 

We aim to update this page on a regular basis. If you are aware of a funder update we have missed or would like a funder added to the list please email

For a list of new funding opportunities available in relation to COVID-19 related research click here.

Some useful articles regarding working from home.


COVID-19 Research Project Tracker by UKCDR & GloPID-R

GloPID-R and UKCDR have developed a live database of funded research projects on COVID-19 that will help funders and researchers identify gaps and opportunities and inform future research investments or coordination needs.


Useful links


Academy of Medical Sciences

Coronavirus (Covid-19) FAQ for AMS applicants and Award holders

AMS will be updating this page regularly in response to the queries we receive from our community. Please continue to contact your primary contacts at the Academy, details for whom can be found on our individual scheme pages. For general queries, please contact  For up to date information on the Academy’s response to Covid-19, please see our information hub.


British Academy

Award holders should follow the advice of their institution and that of the government. 

The British Academy encourages award holders to investigate, where necessary, all possible alternative ways of continuing to progress their research. However, they understand that the outbreak may impact on the activities associated with some awards and will treat all requests for no-cost extensions to awards and requests for virement of funding between cost headings sympathetically. These should be requested in the usual way. 

If you have been unable to recover costs from a travel operator or insurance, costs can be charged to grants. Grants often end with an underspend and the British Academy expects award holders to be able to absorb these costs through this and other re-arrangements in their budgets. 


British Heart Foundation

The NIHR-BHF Cardiovascular Partnership brings together researchers from across the NIHR and the BHF-funded infrastructure to develop collaborative initiatives. Leaders from the partnership came together to form a framework for supporting Covid-19 research projects across the UK. Seven Covid-19 flagship projects have been approved and applications are now closed.


Cancer Research UK

Cancer Research UK defers funding panels amid Covid-19

CRUK has made the difficult decision to defer all their panels and committees. All applications submitted for the current funding round will be considered in the autumn. Where an application has been made for the renewal of an existing grant, bridge-funding will be provided.

Full statement from CRUK and more news


European Commission

Welcome to the European Research Area corona platform.

The platform is a one-stop shop providing comprehensive information about funding opportunities in relation to Coronavirus at European Union and national level.


Knowledge Transfer Network

KTN has established a Covid-19 hub containing information about funding, links to online events, requests for support to help combat Covid-19 and its impact and links to business support sites. Click here to visit the page. 



Leverhulme Trust

Coronavirus (COVID-19)
Information for applicants and grant holders. The Trust will continue to review their policies and will update this page when they have new information.  Please email for enquiries.




27 March 2020

The US’s NIH have published a compliance notice over “Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19”, from a post-award perspective the headlines are:


NIH understands that many researchers may be unable to work as a result of or related to the effects of COVID-19. If a recipient organization’s policy allows for the charging of salaries and benefits during periods when no work is performed due to the effect of COVID-19, regardless of the funding source, including Federal and non-Federal, then such charges to NIH grant awards will be allowable.

Reminder: NIH awarding Institutes/Centers (ICs) may request documentation to confirm the requirements of institutional policies.


Institutions affected by COVID-19 may continue to provide stipend payments to fellows and trainees who may be unable to work as a result of or related to COVID-19. Recipients should notify the assigned grants management official, and provide documentation demonstrating the effect of COVID-19, and how long the institution will be affected.


Non-refundable costs associated with grant-related travel that has been cancelled due to COVID-19 may be charged to the NIH award if they would have otherwise been allowable. See NIH GPS 7.9.1 for detailed information on the allowability of travel expenses.

Conference Registration Fees:

Non-refundable registration fees for conferences, symposiums or seminars that have been cancelled due to COVID19 may be charged to the NIH award if they would have otherwise been allowable (e.g. necessary to accomplish program objectives

Full NIH statement here


When delays occur because the applicant or recipient organisation is officially closed or unable to submit grant applications due to the effects of COVID-19, the NIH will consider accepting applications late, on a case-by-case basis, under certain circumstances.

The NIH has introduced flexibilities applicable to NIH applicants and recipients where the entity is conducting research activities related to or affected by COVID-19, relating to:

  • pre-award costs
  • extension of post-award financial and other reporting
  • prior approval requirement waivers
  • cost-related flexibilities/expenditure of award funds
  • extension of closeout
  • extension of single audit submission

The NIH has issued guidance on clinical trials and human subject studies affected by COVID-19. They encourage recipients to consult with their institutions about potential measures to protect participants and research staff. Recipients may submit late financial and progress reports if research is delayed due to COVID-19, and may carry over unobligated balances on active grants without requesting prior approval.

Frequently asked questions on proposal submission and award management related to COVID-19 are also available:


NIH: National Institute of Mental Health

Notice of special interest – administrative supplements for COVID-19 impacted NIMH research. This provides additional funding for researchers whose investigations have been impacted by COVID-19. 



Researchers currently seeking funding for COVID-19 research can apply through the  NIHR programme researcher-led calls, which welcome COVID-19 research proposals within the remit of their programmes. 


Royal Society

This page will be regularly updated as they assess the potential impacts of the evolving global health situation. Please ensure you regularly check this page for updates as we make further updates to theire advice and guidance.

The Royal Society offices at Carlton House Terrace, London shut from 5pm on Wednesday 18 March and all staff are currently working remotely. You will continue to be able to contact the grants team with any enquiries via or +44 (0)20 7451 2666.

For queries relating to specific grants programmes, see their contacts page  



Guidance for applicants, students and award-holders impacted by the pandemic 

Tackling the impact of COVID-19  

After December the UKRI changed how it funds research into COVID-19.

The UKRI has moved to an embedded programme of funding opportunities. See UKRI current priority areas for Covid 19 funding

This will include:

  • standard Research Council and Innovate UK channels, with tools available to flag up any COVID-19-related research;
  • seed funding for urgent applications;
  • further UKRI strategic COVID-19 funding calls during 2021;
  • future funding calls from individual Research Councils tailored to tackling aspects of the pandemic;
  • Innovate UK Smart Grants.

Top tips!

  • Check the UKRI database and UKCDR database of COVID related projects already funded to make sure your idea is new.
  • If you are in the process of applying to the 15 December deadline, check the UKRI priority areas and make sure your research is not out of scope.
  • If your research will have longer term impact apply through the standard research council route now – you don’t have to wait until the Open Call closes.
  • Check out Research Professional and set up alerts to make sure you are up to date with news and calls.  Contact Research & Innovation if you have a problem setting up your search or accessing Research Professional.
  • Look at our Research 2020 Hub for information and updates on applying for research funding and contact details for everyone in R&I.



Universities UK

These pages offer information and resources for universities on Covid-19, answers to frequently asked questions, and details of how universities can help their communities during this difficult time. 


Coronavirus (Covid-19): information for grant applicants and grant holders
This page has information for anyone applying for one of their research grants, or who holds a Wellcome grant. They will continue to review their policies and will update this page when they have new information. 


World Health Organisation (WHO)- Coronavirus disease (COVID-2019) R&D

Global research and innovation forum: towards a research roadmap

On 30 January 2020, following the recommendations of the Emergency Committee, the WHO Director-General declared that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC). World scientists on COVID-19 met at the World Health Organization’s Geneva headquarters from 11 to 12 February 2020 to assess the current level of knowledge about the new virus, agree on critical research questions that need to be answered urgently, and ways to work together to accelerate and fund priority research that can contribute to curtail this outbreak and prepare for future outbreaks.

As part of WHO’s response to the outbreak, the R&D Blueprint has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus.

Further details here